GlassScriptPhysician profile
Drew Gregory Davis
NPI 1518301720
$660.60
in general payments reported to CMS, 2019-2025
7 companies · $225 in 2025
The $225 reported for 2025 was more than what 80% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.13 · 2021: $23.03 · 2022: $228 · 2023: $31.30 · 2024: $138 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $227.99 | 2022 | |
| Motiva USA, LLC | $224.65 | 2025 | |
| Siemens Medical Solutions USA, INC. | $71.69 | 2020-2024 | Atellica Ch 930 Analyzer, Atellica Im 1300 Analyzer |
| Tempus Ai, INC | $59.27 | 2024 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $40.55 | 2023-2024 | Tagrisso |
| Merck Sharp & Dohme LLC | $21.65 | 2024 | Keytruda, Welireg |
| Medline Industries LP | $14.80 | 2024 | Medline Industries, INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.